| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | liraltagene autoleucel (lira-cel) recurrent ovarian cancer | Phase 1 | — | Cell Therapies | Oncology | ||
Phase 1 data readout example | liraltagene autoleucel (lira-cel) recurrent ovarian cancer | Phase 1 | — | Cell Therapies | Oncology | ||
Phase 1 data readout example | liraltagene autoleucel (lira-cel) recurrent ovarian cancer | Phase 1 | — | Cell Therapies | Oncology |
Recent Updates
Recently added Catalysts
Anixa Biosciences, Inc.$2.6
-0.09 (-3.35%)
D 30Pipeline Score Richly Valued Biotech · Clinical
Market Cap
85.50 M
EPS
-0.32
P/E Ratio
-8.1 $
Value Trade
227.21 K
SEC Financials
Q2 2026Dilution Risk
25%R&D Expenses
1.26 M
Total Assets
14.87 M
Total Liabilities
1.64 M
Equity
14.47 M
D/E Ratio
12,345
-1.76 %
Week
-5.1 %
1 Month
-3.12 %
3 Month
-36.3 %
6 Month
-33.25 %
5 Year
-84.44 %
All Time
Cash Data
Cash Position
13.69 M
Monthly Burn
882.00 K
Runway
15.2 mo
Burn Trend
StableSEC Filing
Jun 10, 2026
Overview
Volume
80.28 K
52 Week Range
2.44 - 5.46
% held by Insiders
5.38 %
% held by Institutions
14.97 %
Enterprise Value
70.26 M
Total Shares
33.51 M
Short %
3.15 %
Float Shares
22.15 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D30
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 37%
Micro Cap (rank 571 of 905)
Percentile RankAnixa Biosciences, Inc. faces pipeline headwinds (30/100), with $38M risk-adjusted pipeline value, led by α-lactalbumin vaccine in Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| α-lactalbumin vaccine Monoclonal antibody | Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer | Phase 1 | NCT04674306 | 9% | $31M | ACTIVE NOT_RECRUITING | 35 | - | - | May 1, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CAR-T therapy | recurrent ovarian cancer | Phase 1 | 2025-06-23 | |||
CAR-T therapy | recurrent ovarian cancer | Phase 1 | 2025-06-23 | |||
CAR-T therapy | recurrent ovarian cancer | Phase 1 | 2025-06-23 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ANIX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Anixa Biosciences, Inc. (ANIX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ANIX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANIX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANIX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANIX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ANIX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ANIXAnixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Anixa Biosciences announced the presentation of two clinical-stage immunotherapy programs at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium. The presentations will cover their ovarian cancer CAR-T therapy, lira-cel, which shows positive survival data, and a breast cancer vaccine that met all primary endpoints in its Phase 1 trial. These presentations underscore Anixa's collaborations with leading cancer research institutions.
Read more →ANIXAnixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
Anixa Biosciences has received a Notice of Allowance from the Canadian Intellectual Property Office for its ovarian cancer vaccine technology. This patent, licensed from Cleveland Clinic, aims to elicit an immune response targeting the AMHR2 protein. The technology is part of a broader strategy to develop cancer vaccines, complementing existing U.S. patent protections. Anixa's collaboration with Cleveland Clinic and NCI highlights its innovative approach to cancer prevention and treatment.
Read more →ANIXAnixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
Anixa Biosciences has reported promising survival data from its ongoing Phase 1 trial of lira-cel, a CAR-T therapy for recurrent ovarian cancer. Patients have shown substantial survival beyond the expected median, with one individual living for 28 months. The therapy is being evaluated for safety and efficacy, with no significant adverse effects noted thus far.
Read more →ANIXAnixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Anixa Biosciences will feature an interview with CEO Dr. Amit Kumar on Bloomberg TV, discussing the company's advancements in cancer treatment. The segment will highlight the positive results from a Phase 1 trial of their breast cancer vaccine and the encouraging survival data from their ovarian cancer CAR-T therapy. This interview aims to showcase Anixa's innovative approach and business model.
Read more →ANIXAnixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
Anixa Biosciences announced that Cheryl Cox will present at the ISCT 2026 Annual Meeting about the Phase 1 trial of lira-cel, a CAR-T therapy targeting ovarian cancer. The presentation will cover the trial's design and objectives, showcasing the ongoing positive survival data. The conference will gather global experts in cell and gene therapy.
Read more →ANIXAnixa Biosciences to Participate in RedChip’s Biotech Resurgence: Platforms and Pipelines of Today’s Innovators Conference on April 16, 2026
Anixa Biosciences will participate in the RedChip Biotech Resurgence conference on April 16, 2026. Dr. Amit Kumar will present updates on the company's breast cancer vaccine, which has met primary endpoints in Phase 1 trials, and the ovarian cancer CAR-T therapy lira-cel, which is showing promising survival data. The conference aims to connect investors with biopharma innovators.
Read more →ANIXAnixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026
Anixa Biosciences will participate in the RedChip Biotech Resurgence conference on April 16, 2026. The company's breast cancer vaccine has successfully met its primary endpoints in a Phase 1 trial, with 74% of participants showing immune responses. Additionally, their ovarian cancer CAR-T therapy, lira-cel, is demonstrating positive survival data in an ongoing Phase 1 trial.
Read more →ANIXAnixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
Anixa Biosciences' CEO, Dr. Amit Kumar, discussed the company's advancements in cancer immunotherapy during an interview. The breast cancer vaccine has successfully completed a Phase 1 trial, achieving its primary endpoints, while the ovarian cancer CAR-T therapy is showing promising survival data in an ongoing Phase 1 trial. Anixa's innovative approach focuses on collaboration with leading research institutions.
Read more →ANIXAnixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
Anixa Biosciences has announced positive results from its Phase 1 study of a breast cancer vaccine, which met all primary endpoints and demonstrated safety and tolerability. The company is now preparing for a Phase 2 clinical trial, supported by a manufacturing agreement with Cytovance Biologics to produce clinical materials. The vaccine targets a protein associated with breast cancer, aiming to provide therapeutic and preventive benefits.
Read more →ANIXAnixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
Anixa Biosciences announced that Dr. Robert Wenham will present the status of its Phase 1 clinical trial for lira-cel, a CAR-T therapy for recurrent ovarian cancer, at the Society of Gynecologic Oncology Annual Meeting. The presentation will cover the trial's design and objectives, emphasizing the innovative targeting of the follicle-stimulating hormone receptor. This event is a significant opportunity for networking and sharing advancements in gynecologic oncology.
Read more →ANIXAnixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
Anixa Biosciences' CEO, Dr. Amit Kumar, was featured on the Water Tower Research podcast, discussing positive clinical trial results for their breast cancer vaccine and ovarian cancer CAR-T therapy. He also outlined the company's future plans and financial health. Anixa's collaborations with leading research institutions enhance its innovative cancer treatment portfolio.
Read more →ANIXAnixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences has received a Notice of Allowance for a patent from the Korean Ministry of Intellectual Property for its breast cancer vaccine technology. This patent enhances Anixa's global intellectual property coverage and supports its ongoing clinical development efforts. The vaccine has demonstrated promising immune responses in a Phase 1 trial, indicating potential for future commercialization.
Read more →ANIXAnixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
Anixa Biosciences will host its 2026 Annual Meeting on March 10, 2026, featuring a corporate update on its oncology pipeline. The meeting will include a presentation by CEO Dr. Amit Kumar, discussing recent clinical progress, particularly in ovarian and breast cancer treatments. The event is accessible to all interested parties.
Read more →ANIXAnixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Anixa Biosciences announced that Dr. Jose Conejo-Garcia will deliver a keynote speech at the SCTR 2026 Retreat, focusing on the company's Phase 1 clinical trial of lira-cel, a CAR-T therapy for recurrent ovarian cancer. The retreat aims to connect leaders in research and clinical care to advance cell-based therapies. Anixa's innovative approach targets cancer cells while sparing healthy tissue.
Read more →ANIXAnixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Anixa Biosciences reported encouraging results from its Phase 1 CAR-T trial for ovarian cancer, where several patients exceeded expected survival rates. Following a clean safety profile with no dose-limiting toxicities, the company received regulatory approval to escalate doses significantly. The trial aims to enhance efficacy through intra-peritoneal delivery and lymphodepletion.
Read more →ANIXAnixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Anixa Biosciences announced the USAN Council's approval of 'liraltagene autoleucel' as the non-proprietary name for its CAR-T therapy targeting recurrent ovarian cancer. This approval follows international recognition by the WHO and is seen as a crucial step towards commercialization. The company continues its Phase 1 trial in partnership with Moffitt Cancer Center.
Read more →ANIXAnixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences has received a Notice of Allowance from the Mexican Institute of Industrial Property for a patent related to its breast cancer vaccine technology. This patent enhances Anixa's global intellectual property portfolio, particularly in markets with high rates of late-stage and triple-negative breast cancer. The vaccine aims to improve cancer prevention and treatment strategies.
Read more →ANIXAnixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
Anixa Biosciences has successfully transferred the IND for its breast cancer vaccine from Cleveland Clinic, becoming the trial sponsor. Following positive results from the Phase 1 trial, the company aims to initiate a Phase 2 clinical trial utilizing multiple clinical sites. The vaccine targets a protein associated with breast cancer, potentially offering therapeutic benefits.
Read more →ANIXAnixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Anixa Biosciences announced positive results from its Phase 1 trial of an investigational breast cancer vaccine, which met all primary endpoints and demonstrated an immune response in 74% of participants. The vaccine was found to be safe and well tolerated, with no major adverse side effects reported. The company plans to advance the program into Phase 2 development.
Read more →ANIXAnixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Anixa Biosciences will participate in the Water Tower Research Fireside Chat on December 15, 2025. CEO Dr. Amit Kumar will discuss various topics related to the company's innovative cancer treatments. The event is open to all investors, providing an opportunity for engagement and insight into Anixa's ongoing projects.
Read more →ANIXAnixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
Anixa Biosciences has received approval from the WHO for the non-proprietary name 'liraltagene autoleucel' for its CAR-T therapy targeting recurrent ovarian cancer. This approval is a crucial step towards commercialization and global recognition of the therapy. The company is currently conducting a Phase 1 trial in collaboration with Moffitt Cancer Center, focusing on safety and clinical activity.
Read more →ANIXAnixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
Anixa Biosciences has announced the issuance of a key U.S. patent for its breast cancer vaccine technology, extending protection into the mid-2040s. This patent covers methods to induce an immune response to the α-lactalbumin protein, which is present in certain breast cancers. The vaccine aims to prevent breast cancer by targeting this protein while sparing normal tissue, addressing a critical unmet need in preventive oncology.
Read more →ANIXAnixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
Anixa Biosciences has executed a data transfer agreement with Cleveland Clinic, marking a crucial step in transferring IND sponsorship for its breast cancer vaccine. Following positive results from the Phase 1 trial, Anixa is set to advance to a Phase 2 trial. The vaccine targets a protein associated with breast cancer, potentially offering therapeutic benefits.
Read more →ANIXAnixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
Anixa Biosciences, a biotechnology company focused on cancer treatment, will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025. Mike Catelani, the President and CFO, will deliver a presentation and engage in one-on-one meetings. The event will feature various companies and is expected to attract over 500 investors.
Read more →ANIXAnixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences has received a new patent from the Chinese National Intellectual Property Administration for its breast cancer vaccine technology, which is expected to enhance its global intellectual property coverage. This patent will protect the technology until 2040 and supports Anixa's ongoing clinical development efforts. The vaccine aims to prevent breast cancer by targeting a specific protein associated with the disease.
Read more →ANIXAnixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial
Anixa Biosciences has completed the final patient visit in its breast cancer vaccine clinical trial, a significant milestone in its first-in-human evaluation. The trial, which enrolled 35 women, aims to stimulate the immune system to target breast cancer. Comprehensive data analysis will follow, with results to be presented at the San Antonio Breast Cancer Symposium in December.
Read more →ANIXCleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium
Anixa Biosciences announced that the final results of its Phase 1 clinical trial for a breast cancer vaccine will be presented at the 2025 San Antonio Breast Cancer Symposium. The trial, conducted at Cleveland Clinic, evaluated the safety and immunogenicity of the alpha-lactalbumin vaccine. The findings will inform FDA discussions and advance plans for Phase 2 development.
Read more →Competitive Position
How ANIX ranks across every disease it competes inCompetitive Position is a premium feature
See how ANIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial